Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search)
-
1621
Correlation between immune function indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: -
1622
-
1623
Demographics and clinical features of healthy controls and primary Sjögren’s Syndrome patients.
Published 2025Subjects: -
1624
Anonymized clinical datasets (patient demographics, medical imaging, and laboratory test records).
Published 2025Subjects: -
1625
Correlation between biochemical indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: -
1626
Correlation between immune function indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: -
1627
-
1628
-
1629
-
1630
-
1631
-
1632
Differential expression of acute rejection markers between C1 and C2 clusters.
Published 2024Subjects: -
1633
-
1634
-
1635
-
1636
-
1637
Unsupervised hierarchical clustering for benign samples only (nontreatment, STT, and LTT groups).
Published 2025Subjects: -
1638
-
1639
Combined Morphological and IHC Data: Combined Morphological and Immunohistochemistry Data.
Published 2025Subjects: -
1640
Morphologic changes after dihydrotestosterone (DHT) treatment.1A: Diffuse lobular atrophy (20x).
Published 2025Subjects: